Premium
Rituximab‐combination chemotherapy achieves a 10th cycle of remission for B urkitt's lymphoma
Author(s) -
Umeda Katsutsugu,
Fujino Hisanori,
Saida Satoshi,
Kato Itaru,
Hiramatsu Hidefumi,
Yamada Tomomi,
Hori Toshinori,
Adachi Souichi,
Heike Toshio,
Watanabe KenIchiro
Publication year - 2015
Publication title -
pediatrics international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.49
H-Index - 63
eISSN - 1442-200X
pISSN - 1328-8067
DOI - 10.1111/ped.12524
Subject(s) - medicine , etoposide , rituximab , chemotherapy , lymphoma , complete remission , surgery , regimen , bone marrow , cyclophosphamide , combination chemotherapy , oncology , gastroenterology
A 14‐year‐old girl with multiple intra‐abdominal tumors was diagnosed with stage III B urkitt's lymphoma. She achieved complete remission after multi‐drug chemotherapy, but she relapsed after six courses. Autologous peripheral blood stem cells ( PBSC ) or allogeneic PBSC harvested from an HLA ‐identical sibling were insufficient, and her family did not agree to bone marrow collection from the sibling. Although the patient relapsed nine times (the relapses involved intra‐abdominal organs or bone) during the following 4 years 7 months, treatment with rituximab monotherapy or in combination with ifosphamide, carboplastin, and etoposide, or local irradiation (33.8–40.0 Gy) to treat the bone metastases, proved effective, resulting in complete or partial remission. At the time of writing, the patient was in a 10th cycle of remission lasting 1 year 6 months and had not required transplantation. Thus, a chemotherapy regimen including rituximab might be effective for Burkitt's lymphoma in patients experiencing multiple relapse.